Recent advances in the management of Crohn's disease

Abstract In the last 10 years many advances have been achieved in the treatment of patients with Crohn's disease, particularly in the field of biological agents. Infliximab, a tumour necrosis factor alpha antagonist, has been recently added to the therapeutic armamentarium for Crohn's dise...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2008-09, Vol.40 (9), p.709-716
Hauptverfasser:	Caprilli, R, Angelucci, E, Clemente, V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Algorithms Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological Products - therapeutic use C-Reactive Protein - drug effects C-Reactive Protein - metabolism Certolizumab Certolizumab Pegol Crohn Disease - diagnosis Crohn Disease - mortality Crohn Disease - therapy Female Gastroenterology and Hepatology Hematopoietic Stem Cell Transplantation Humans Immunoglobulin Fab Fragments - therapeutic use Immunosuppressive Agents - therapeutic use Infliximab Laparoscopy - methods Male Marrow transplantation Natalizumab Polyethylene Glycols - therapeutic use Prognosis Randomized Controlled Trials as Topic Risk Assessment Sensitivity and Specificity Severity of Illness Index Survival Rate Thiopurines Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!